[1]王 敏,陈 阁.清热化痰祛瘀方联合西药治疗慢性阻塞性肺疾病急性 加重期患者的临床研究[J].陕西中医,2019,(5):610-612.
　WANG Min,CHEN Ge..Clinical study of Qingre Huatan Quyu prescription combined with western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].,2019,(5):610-612.
点击复制

清热化痰祛瘀方联合西药治疗慢性阻塞性肺疾病急性 加重期患者的临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年5期
页码:
610-612
栏目:
临床研究
出版日期:
2019-05-05

文章信息/Info

Title:
Clinical study of Qingre Huatan Quyu prescription combined with western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease
文章编号:
DOI:〖HT5K〗10.3969/j.issn.1000-7369.2019.05.019
作者:
王 敏1; 陈 阁
1.西安高新医院(西安 710075);2.陕西省体育科学研究所（西安710065）
Author(s):
WANG Min; CHEN Ge.
Xi’an Gaoxin Hospital(Xi’an 710075)
关键词:
慢性阻塞性肺疾病; 清热化痰祛瘀方; 肺功能; 中医症候; 安全性; 第1秒用力呼气容积
Keywords:
COPD; Qingre Huatan Quyu prescription; Pulmonary function; TCM syndrome; Safety ;  FEV1
分类号:
R563
文献标志码:
A
摘要:
摘 要 目的：探讨清热化痰祛瘀方联合西药治疗慢性阻塞性肺疾病急性加重期（COPD）患者的临床疗效及安全性。方法：选取就诊并确诊为COPD的患者104例，按随机数字表法分为对照组和观察组，每组各52例，对照组采取常规西医治疗，观察组在对照组基础上联合清热化痰祛瘀方治疗，两组均治疗1周后，观察两组临床疗效、中医症候积分改善情况及安全性，同时观察两组治疗前后第1秒用力呼气容积（FEV1）、第1秒用力呼气容积占用力肺活动比值（FEV1/FVC）肺功能指标变化。结果：与治疗前相比，两组治疗后中医症候积分均有所降低，且观察组高于对照组（P<0.05）；与治疗前相比，两组治疗后FEV1、FEV1/FVC水平均升高，且观察组高于对照组（P<0.05）；观察组治疗总有效率高于对照组（P<0.05）；而两组均未见皮疹、恶心、呕吐等不良反应。结论：采取西医联合清热化痰祛瘀方治疗方案，能改善COPD患者肺功能及临床症状，且用药安全。
Abstract:
Abstract Objective:To explore the clinical efficacy and safety of Qingre Huatan Quyu rescription combined with western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD).Methods:104 patients who were diagnosed and diagnosed as COPD were selected,they were randomly divided into control group and observation group according to random number table,52 cases in each group.The control group was treated with conventional western medicine.The observation group was treated with Qingre Huatan Quyu rescription on the basis of the control group.After 1 week of treatment in two groups,the clinical efficacy,improvement of TCM symptom score and safety of the two groups were observed.The changes of the first second forced expiratory volume (FEV1) and the first second forced expiratory volume occupancy ratio (FEV1/FVC) of the two groups before and after treatment were also observed.Results:Compared with before treatment,the TCM symptom scores in the two groups were reduced after treatment,and those in the observation group were higher than those in the control group (P<0.05).Compared with before treatment,the levels of FEV1 and FEV1/FVC in both groups were increased after treatment,and those in the observation group were higher than those in the control group (P<0.05).The total effective rate of the observation group was higher than that of the control group (P<0.05), and there were no adverse reactions such as rash,nausea and vomiting in the two groups.Conclusion:Western medicine combined with Qingre Huatan Quyu rescription can improve the lung function and clinical symptoms of COPD patients,and the medication is safe.

参考文献/References:

[1] 高雅丽.清热化痰方治疗慢性阻塞性肺疾病急性加重期痰热壅肺证的临床疗效 [J].临床合理用药杂志,2016,9(36):87-88.
[2] 蒋紫云,连乐燊,王 婷,等.清热化痰联合低剂量激素治疗慢性阻塞性肺疾病急性加重期随机平行对照研究 [J].实用中医内科杂志,2016,30(5):66-68.
[3] 中华内科杂志.慢性阻塞性肺疾病诊治指南(2007年修订版) [J].中华结核和呼吸杂志,2007, 46(1):254-260.
[4] 陈 晓,何和章,林 容,等.慢性阻塞性肺疾病急性加重期住院患者病毒感染危险因素分析 [J].中华医院感染学杂志,2016,26(19):4452-4454.
[5] 王小仁,李亚洁,张立颖,等.慢性阻塞性肺疾病患者生存质量调查及影响因素分析 [J].重庆医学,2016,45(19):2661-2663.
[6] 李 允,罗裕文,郑晶晶,等.慢性阻塞性肺疾病急性加重期住院患者呼吸道病毒病原学分布及危险因素分析 [J].中国现代医学杂志,2016,26(6):80-84.
[7] Kim YS, Hong G, Kim DH,et al.The role of FGF-2 in smoke-induced emphysema and the therapeutic potential of recombinant FGF-2 in patients with COPD [J].Exp Mol Med,2018,50(11):150.
[8] 江枫然.清热化痰理气中药复方治疗急性加重期慢性阻塞性肺疾病的效果 [J].中国现代药物应用,2017,11(22):185-186.
[9] Louis R,Ziant S,Duchesnes C,et al.Exacerbations in asthma and chronic obstructive pulmonary disease (COPD) Survey on the criteria of pescription of systemic corticoids and antibiotics by general practicioners and chest physicians [J].Rev Med Liege,2018,73(11):570-574.
[10] 曹宗黎.清热化痰法治疗慢性阻塞性肺疾病急性加重期78例疗效观察 [J].光明中医,2016,31(1):68-69.

相似文献/References:

[1]杨栓柱,王 文 △,李 猛,等.千金苇茎汤合瓜蒌薤白杏仁汤治疗 慢性阻塞性肺疾病急性加重期临床研究*[J].陕西中医,2019,(5):600.
[2]李天浩,韩晨旭,王惠琴,等.基于EGFR-MUC5AC信号通路探讨参鱼化痰口服液干预慢性阻塞性肺疾病大鼠气道黏液高分泌的机制*[J].陕西中医,2019,(8):995.
　LI Tianhao,HAN Chenxu,WANG Huiqin,et al.Based on EGFR-MUC5AC signaling pathway to explore the mechanism of Shenyu Huatan oral liquid in intervention of airway mucus high secretion in COPD rats[J].,2019,(5):995.
[3]王珊珊,谭光波△.补肺汤对慢性阻塞性肺疾病肺气肿大鼠血清IFNγ、IL4表达水平影响研究*[J].陕西中医,2019,(11):1491.
　WANG Shanshan,TAN Guangbo..Effect of Bufei decoction on the expression of IFNγ and IL4 in serum of rats with chronic obstructive pulmonary disease and emphysema[J].,2019,(5):1491.
[4]任英杰,王 起,陈秋生.黄芪汤加减治疗急性加重期慢性阻塞性肺疾病疗效研究[J].陕西中医,2020,(1):57.
　REN Yingjie,WANG Qi,CHEN Qiusheng..Observation on the curative effect of Huangqi decoction in the treatment ofacute exacerbation of chronic obstructive pulmonary disease[J].,2020,(5):57.
[5]聂清华,范伏元△.射干麻黄汤联合沙丁胺醇对慢性阻塞性肺疾病患者肺功能、生活质量的影响[J].陕西中医,2020,(2):180.
　NIE Qinghua,FAN Fuyuan..Effects of Shegan Mahuang decoction and albuterol on pulmonary function and quality of life in patients with COPD[J].,2020,(5):180.
[6]刘新平,王展儒.理肺化痰通脉方治疗慢性阻塞性肺疾病急性加重期临床研究[J].陕西中医,2020,(4):484.
[7]杜沂岚,唐 敏,陈朝晖△,等.经肺腧穴中药离子导入联合振动排痰治疗慢性阻塞性肺疾病急性加重期临床疗效*[J].陕西中医,2020,(4):534.
　DU Yilan,TANG Min,CHEN Zhaohui,et al.Clinical efficacy of Chinese medicine iontophoresis via Feishu point combined with vibration sputum discarding in the treatment of AECOPD[J].,2020,(5):534.
[8]唐颖丽,谢 珊,余清萍,等.子午流注法治疗慢性阻塞性肺疾病加重期痰浊阻肺证疗效研究*[J].陕西中医,2020,(9):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
　TANG Yingli,XIE Shan,YU Qingping,et al.Curative effect of midnight-noon ebb-flow method on chronic obstructive pulmonary disease exacerbation with syndrome of Tanzhuo Zufei[J].,2020,(5):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
[9]蔡东林,孙钟和,赵益庆.慢性阻塞性肺疾病稳定期BODE指数、IL-8、TNF-α水平与肺肾气虚证相关性研究*[J].陕西中医,2020,(11):1573.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.015]
[10]武胜举,王晓青,姚惠青.补肾活血膏方对慢性阻塞性肺疾病稳定期患者抑郁焦虑状态的影响[J].陕西中医,2021,(1):45.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.010]

更新日期/Last Update: 2019-05-07